[
    {
        "title": "Beckman Coulter, Siemens Healthineers, Abbott, Others Gain 510(k) Clearances in March",
        "summary": "<p><span><span><span>The US Food and Drug Administration granted clearances for testing instruments, a blood clot drug companion diagnostic test, and infectious disease tests, among other devices.</span></span></span></p>",
        "link": "https://www.360dx.com/regulatory-news-fda-approvals/beckman-coulter-siemens-healthineers-abbott-others-gain-510k",
        "published": "Wed, 16 Apr 2025 14:35:26 EDT",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "Agilent Gains IVDR Certification for Expanded Use of CDx Assay for Keytruda",
        "summary": "<p><span><span><span>The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/agilent-gains-ivdr-certification-expanded-use-cdx-assay-keytruda",
        "published": "Thu, 17 Apr 2025 10:04:09 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "EntroGen Colorectal Cancer RAS Mutation Detection Test Nabs CMS Coverage",
        "summary": "<p><span><span><span>The real-time PCR-based companion diagnostic test identifies patients eligible for treatment with Amgen's Vectibix (panitumumab). </span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/entrogen-colorectal-cancer-ras-mutation-detection-test-nabs-cms-coverage",
        "published": "Mon, 28 Apr 2025 14:27:37 EDT",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "EntroGen Colorectal Cancer RAS Mutation Detection Test Nabs CMS Coverage",
        "summary": "<p><span><span><span>The real-time PCR-based companion diagnostic test identifies patients eligible for treatment with Amgen's Vectibix (panitumumab). </span></span></span></p>",
        "link": "https://www.360dx.com/cancer/entrogen-colorectal-cancer-ras-mutation-detection-test-nabs-cms-coverage",
        "published": "Mon, 28 Apr 2025 14:27:37 EDT",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "<a href=\"https://www.fiercebiotech.com/medtech/roche-receives-fda-breakthrough-label-ai-powered-lung-cancer-companion-diagnostic-test\" hreflang=\"en\">Roche receives FDA breakthrough label for AI-powered lung cancer companion diagnostic test</a>",
        "summary": "Roche\u2019s companion diagnostic aims to identify non-small cell lung cancer patients who may benefit from Datroway, an antibody-drug conjugate developed by AstraZeneca and Daiichi Sankyo.",
        "link": "https://www.fiercebiotech.com/medtech/roche-receives-fda-breakthrough-label-ai-powered-lung-cancer-companion-diagnostic-test",
        "published": "Apr 29, 2025 12:05pm",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "FDA Approves Roche Lung Cancer CDx Assay for Use with AbbVie's Emrelis",
        "summary": "<p><span><span><span>The test detects the MET protein that is over-expressed in some patients with non-squamous non-small cell lung cancer. </span></span></span></p>",
        "link": "https://www.360dx.com/cancer/fda-approves-roche-lung-cancer-cdx-assay-use-abbvies-emrelis",
        "published": "Wed, 14 May 2025 17:26:50 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Tempus AI, Verastem Partner to Develop CDx Assay for Ovarian Cancer Combination Treatment",
        "summary": "<p><span><span><span>Tempus' FDA-approved xT CDx test is being used as an investigational assay in Verastem's global Phase III RAMP-301 clinical trial. </span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/tempus-ai-verastem-partner-develop-cdx-assay-ovarian-cancer-combination-treatment",
        "published": "Tue, 20 May 2025 09:31:24 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Tempus AI, Verastem Partner to Develop CDx Assay for Ovarian Cancer Combination Treatment",
        "summary": "<p><span><span><span>Tempus' FDA-approved xT CDx test is being used as an investigational assay in Verastem's global Phase III RAMP-301 clinical trial. </span></span></span></p>",
        "link": "https://www.360dx.com/cancer/tempus-ai-verastem-partner-develop-cdx-assay-ovarian-cancer-combination-treatment",
        "published": "Tue, 20 May 2025 09:31:24 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "ODAC votes for Darzalex in smoldering multiple myeloma",
        "summary": "<div class=\"title-top\">MAY 23, 2025 | 2:42 PM PDT | BIOCENTURY | DATA BYTE</div><div class=\"title-bottom\">ODAC VOTES FOR DARZALEX IN SMOLDERING MULTIPLE MYELOMA</div><div class=\"byline\">BY </div>Three other products get negative committee outcomes<a href=\"https://www.biocentury.com/article/656014/odac-votes-for-darzalex-in-smoldering-multiple-myeloma\">https://www.biocentury.com/article/656014/odac-votes-for-darzalex-in-smoldering-multiple-myeloma</a><a href=\"https://www.biocentury.com/copyright\">\u00a9 2025 BioCentury Inc. All Rights Reserved</a>",
        "link": "https://www.biocentury.com/article/656014/odac-votes-for-darzalex-in-smoldering-multiple-myeloma",
        "published": "Fri, 23 May 2025 14:42:56 -0700",
        "keywords": [
            "smoldering multiple myeloma"
        ]
    }
]